PMID- 35712716
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220716
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 13
DP  - 2022
TI  - Myrtenol Reduces Orofacial Nociception and Inflammation in Mice Through p38-MAPK 
      and Cytokine Inhibition.
PG  - 910219
LID - 10.3389/fphar.2022.910219 [doi]
LID - 910219
AB  - Orofacial pain is one of the commonest and most complex complaints in dentistry, 
      greatly impairing life quality. Preclinical studies using monoterpenes have shown 
      pharmacological potential to treat painful conditions, but the reports of the 
      effects of myrtenol on orofacial pain and inflammation are scarce. The aim of 
      this study was to evaluate the effect of myrtenol in experimental models of 
      orofacial pain and inflammation. Orofacial nociceptive behavior and the 
      immunoreactivity of the phosphorylated p38 (P-p38)-MAPK in trigeminal ganglia 
      (TG) and spinal trigeminal subnucleus caudalis (STSC) were determined after the 
      injection of formalin in the upper lip of male Swiss mice pretreated with 
      myrtenol (12.5 and 25 mg/kg, i.p.) or vehicle. Orofacial inflammation was induced 
      by the injection of carrageenan (CGN) in the masseter muscle of mice pretreated 
      with myrtenol (25 and 50 mg/kg, i.p.) or its vehicle (0.02% Tween 80 in saline). 
      Myeloperoxidase (MPO) activity and histopathological changes in the masseter 
      muscle and interleukin (IL)-1beta levels in the TG and STSC were measured. The 
      increase in face-rubbing behavior time induced by formalin and P-p38-MAPK 
      immunostaining in trigeminal ganglia were significantly reduced by myrtenol 
      treatment (12.5 and 25 mg/kg). Likewise, increased MPO activity and inflammatory 
      histological scores in masseter muscle, as well as augmented levels of IL-1beta in 
      the TG AND STSC, observed after CGN injection, were significantly decreased by 
      myrtenol (25 and 50 mg/kg). Myrtenol has potential to treat orofacial 
      inflammation and pain, which is partially related to IL-1beta levels in the 
      trigeminal pathway and p38-MAPK modulation in trigeminal ganglia.
CI  - Copyright (c) 2022 Oliveira, Abreu, Bispo, Cerqueira, Santos, Correa, Costa and 
      Camargo.
FAU - Oliveira, Janaine P
AU  - Oliveira JP
AD  - Graduate Program in Physiological Sciences, Federal University of Sergipe, Sao 
      Cristovao, Brazil.
AD  - Department of Pharmacology, Institute of Biomedical Sciences, University of Sao 
      Paulo, Sao Paulo, Brazil.
FAU - Abreu, Fabiula F
AU  - Abreu FF
AD  - Graduate Program in Physiological Sciences, Federal University of Sergipe, Sao 
      Cristovao, Brazil.
FAU - Bispo, Jose Marcos M
AU  - Bispo JMM
AD  - Graduate Program in Physiological Sciences, Federal University of Sergipe, Sao 
      Cristovao, Brazil.
FAU - Cerqueira, Anderson R A
AU  - Cerqueira ARA
AD  - Department of Pharmacology, Institute of Biomedical Sciences, University of Sao 
      Paulo, Sao Paulo, Brazil.
FAU - Dos Santos, Jose Ronaldo
AU  - Dos Santos JR
AD  - Graduate Program in Physiological Sciences, Federal University of Sergipe, Sao 
      Cristovao, Brazil.
AD  - Department of Biosciences, Federal University of Sergipe, Itabaiana, Brazil.
FAU - Correa, Cristiane B
AU  - Correa CB
AD  - Graduate Program in Physiological Sciences, Federal University of Sergipe, Sao 
      Cristovao, Brazil.
AD  - Department of Morphology, Federal University of Sergipe, Sao Cristovao, Brazil.
FAU - Costa, Soraia K P
AU  - Costa SKP
AD  - Department of Pharmacology, Institute of Biomedical Sciences, University of Sao 
      Paulo, Sao Paulo, Brazil.
FAU - Camargo, Enilton A
AU  - Camargo EA
AD  - Graduate Program in Physiological Sciences, Federal University of Sergipe, Sao 
      Cristovao, Brazil.
AD  - Department of Physiology, Federal University of Sergipe, Sao Cristovao, Brazil.
LA  - eng
PT  - Journal Article
DEP - 20220530
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC9196033
OTO - NOTNLM
OT  - cytokine
OT  - mitogen-activated protein kinase
OT  - myrtenol
OT  - orofacial pain
OT  - temporomandibular disorder
OT  - terpene
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/06/18 06:00
MHDA- 2022/06/18 06:01
PMCR- 2022/05/30
CRDT- 2022/06/17 02:46
PHST- 2022/04/01 00:00 [received]
PHST- 2022/05/03 00:00 [accepted]
PHST- 2022/06/17 02:46 [entrez]
PHST- 2022/06/18 06:00 [pubmed]
PHST- 2022/06/18 06:01 [medline]
PHST- 2022/05/30 00:00 [pmc-release]
AID - 910219 [pii]
AID - 10.3389/fphar.2022.910219 [doi]
PST - epublish
SO  - Front Pharmacol. 2022 May 30;13:910219. doi: 10.3389/fphar.2022.910219. 
      eCollection 2022.